PSKY has now passed through its July 21 earnings date — but the post-print setup is more interesting than the print itself, with borrowing costs doubling overnight and the stock extending its month-long slide.
The most notable shift this week is in the lending market. Cost to borrow nearly doubled in a single session, jumping from 1.27% on July 20 to 2.80% on July 21 — the highest level since mid-June, when it briefly touched 3.1%. That mid-June spike rapidly faded back below 1.5%, so the current move has precedent as a short-lived flare. Availability remains ample at roughly 100%, meaning there is approximately one share available to lend for every share already borrowed — well off the 52-week trough of just 1.1% availability reached at the tightest point. Short interest has ground higher through the month, adding about 2.5% over the past week to reach roughly 81.4 million shares, with the pace of accumulation modest rather than aggressive. The ORTEX short score has crept to 73.1, up from around 70.9 two weeks ago — a gradual drift toward more bearish positioning, not a sudden squeeze catalyst.
Options positioning has returned to neutral after the pre-earnings call-side tilt noted in last week's earnings preview. The put/call ratio is back at 1.03, almost exactly in line with its 20-day average of 1.04 and just 0.33 standard deviations below it. The pre-earnings bet on upside has unwound cleanly. The 52-week range for the PCR — from 0.0 to 1.90 — shows the market has traded far more bearish extremes on this stock; the current reading is uneventful by comparison.
The Street remains cautious, and the gap between where analysts thought the stock would be and where it trades has widened uncomfortably. The consensus mean price target from the analyst community is $11.79, implying roughly 38% upside from the current $8.53 close — yet the consensus rating is a hold, with 10 analysts neutral, five bearish, and only three with constructive ratings. That distribution matters: the target gap mostly reflects analysts who haven't yet cut targets to match their hold and sell ratings rather than genuine conviction on the upside. The most recent moves, from Wells Fargo and Guggenheim in early May, were both target reductions after the prior earnings print. Morgan Stanley's upgrade to Overweight in May — with a $14 target — is the outlier bull. The P/E multiple has compressed about 16% over the past 30 days to 11.1x, and price-to-book has shed 14% to 0.83x, meaning the stock is getting cheaper on most measures even as the business case has not materially improved. The EV/EBITDA at 5.9x remains the only multiple bears would struggle to call stretched. Factor scores back up the cautious read: the short score ranks in the fourth percentile of the ORTEX universe, and days-to-cover ranks in the eighth.
Insider activity is light and largely technical. Director Dennis Cinelli received a 187,500-share award on July 15 and immediately sold 95,401 shares at $9.25 — a routine tax-withholding sale, not a directional bet. The 90-day insider net is a modest positive of roughly 328,000 shares, but the aggregate $3.4 million net value reflects awards rather than open-market conviction buys. CEO David Ellison holds 30.2% of the company; his May award and concurrent sale followed the same pattern. There is no cluster of open-market purchases signalling that insiders see the current price as an opportunity.
The prior earnings history offers a consistent signal: the two most recent prints each produced a roughly 3.6–3.9% drop the next day, with the May 11 print extending to an 11.5% loss over the following five days. The July 21 event is in the data but carries no price-reaction figures yet — the next print to watch is now the August 3 earnings date. Among the broader peer set, AMCX bucked the sector trend with a 6.2% weekly gain while SSP jumped 16%, underscoring that broadcasting names can move sharply on company-specific catalysts. PUBM fell 5.6% on the week, roughly matching PSKY's 6.5% decline, while SBGI was flat. The divergence within the peer group suggests stock-specific factors, not sector-wide pressure, are driving PSKY's weakness.
The next focal point is the August 3 earnings date — with borrow costs now at a one-month high and the prior two prints both producing multi-day selloffs, the question is whether the cost-to-borrow spike fades again as it did in June, or whether it firms ahead of the next release.
See the live data behind this article on ORTEX.
Open PSKY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
